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Background: Foulds’ Delusions-Symptoms-State Inventory (DSSI) has been purported to be a reliable, systematic
categorical measure to assess the patients with schizophrenia according to the degree of illness. However, further
cross-validations using other clinical measures and diverse samples from other cultures have not been advanced
recently. We aimed to examine the validity of the DSSI hierarchical class model using both Korean non-patient and
patient (schizophrenia and depression) groups.
Method: The hypothesis of inclusive, non-reflexive relationships among the DSSI classes was tested. The power of
DSSI to detect presence of symptoms was assessed via cross-validation with other clinical measures, and the
differences between the clinical features among the DSSI classes were examined using the Minnesota Multiphasic
Personality Inventory (MMPI).
Results: The high rate of model conformity (91.1%) across the samples and cross-validation with other criterion
measures provided further support for the validity of DSSI.
Conclusions: DSSI is a reliable self-report measure that can be applied to both patient and non-patients to assess
the presence and severity of psychiatric illness. Future studies that include more diverse clinical groups are
necessary to lend further support for its utility in clinical practice.
Keywords: Schizophrenia, Self-report measure, Cross-validation, Delusion, Diagnose, Cluster analysis, Hierarchical
class model, PowerBackground
Rich variations in psychopathology of schizophrenia have
always presented challenges for clinicians who have pre-
dominantly relied on descriptive psychopathology for diag-
nosing and evaluating schizophrenia. Ironically, most
traditional conceptualization and nomenclature of schizo-
phrenia have yielded little room to adequately account for
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reproduction in any medium, provided the orexample, given a history of an ‘active phase’ of psychotic
symptomatology, a diagnosis of schizophrenia precedes
other considerations even in the absence of apparent psych-
otic features [1]. While subtypes, such as ‘in remission’ or
‘residual’ could be assigned, their diagnostic reliability, valid-
ity, and clinical utility have shown to be largely inadequate
and hence have been eliminated in DSM-5 [2].
Characterization of the schizophrenia as either/or dichot-
omy following the disease entity model prevails in both
clinical practice and research. However, a notion of con-
tinuum from normality to psychotic illness has been articu-
lated for over a century [3], though it has not been
rigorously pursued except by a group of British researchers
[1]. The severity of illness can be conceived and isLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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diagnose is usually made - in the ascending order of anxiety
and other neuroses, depressive neurosis, manic and para-
noid psychoses, schizophrenia, and then organic psychosis
[4]. Perceivably, such conceptualization of illness is more
likely consider the shifting nature of the illness rather than
diagnosis, which may have some important implications for
treatment and prevention. Individuals with characteristic
attenuated psychotic syndrome are several 100-times more
likely to develop psychotic disorder in the next year than
the general population and present current mood and anx-
iety symptoms [5]. Nonetheless, a significant proportion of
such individuals are identified and provided with interven-
tions much later to prevent substantial damage [6,7].
On the other hand, categorizing patients according to
symptom clusters that reflect the level of illness severity
along the hierarchical path may hold distinct advantages
over other approaches. For example, dimensional ap-
proaches to evaluate the presence and severity of illness may
better reflect the heterogeneity of the patients but they
present difficulties in establishing the range of normality and
inadequacies in accounting for the individual differences in
‘symptom complexes’ and their prognostic value [8].
Overall, a taxonomic system that better reflects het-
erogeneity and fluctuating nature of illness within a con-
tinuum may deserve more in-depth examination for its
validity and applicability in both clinical practice and re-
search. Accordingly, a self-report measure developed to
assess the degree of adverse change in personal func-
tioning and severity of clinical disorder in a hierarchical
arrangement has been proposed previously by Foulds
and Bedford [9]. The central notion is that starting with
those without significant level of illness, or not person-
ally ill (NPI), patients could be categorized according to
a four-class hierarchical model of the severity of mental
illness as follows: dysthymic states (DS) consisting of
manifestations of states of anxiety, depression, and/or
elation; neurotic symptoms (NS) involving conversion,
dissociation, phobia, compulsion, and rumination; inte-
grated delusion (ID) with delusions of persecution,
grandeur, and/or contrition; and delusions of disintegra-
tion (DD) representing a single syndromal group corre-
sponding to schizophrenia with considerable extent of
personal disintegration as an agent of his/her own feel-
ings, thoughts and actions [10,11]. The central hypoth-
esis of this model is inclusive, non-reflexive relationship
among the classes, which simply posits that the mem-
bership in the higher class also entails membership in
the lower ones and that the converse does not hold.
Hence, for example, every patient in ID class has both
neurotic symptoms and dysthymic states but not delu-
sions of disintegration [12].
The rate of concordance to the model has been found
to reach above 90% in the majority of studies [13], withonly a few studies that included narrow diagnostic class,
such as chronic inpatients [14] and manic and hypo-
manic patients [15], showing low percentages of about
73%. The concordance rate of one-month retest by the
original authors of the DSSI reached above 90% [16].
Despite such robust findings regarding the validity of the
hierarchical model, cross-cultural validation and feasibil-
ity of the model have not been actively examined.
In the present study, we examined the validity of the
DSSI hierarchical class model using both Korean non-
patient and patient (schizophrenia and depression)
groups by conducting cross-validations with other clin-
ical measures. We tested the hypothesis of inclusive
non-reflexive relationships among the classes, i.e. hier-
archical organization according to the severity of illness,
assessed the power of the DSSI to detect presence of
symptoms via cross-validation with other clinical mea-
sures, and examined the differences in the clinical fea-
tures among the DSSI classes using the Minnesota
Multiphasic Personality Inventory (MMPI-2).Methods
Subjects
A total of 298 subjects participated in the study but 3
participants (2 non-patients and 1 schizophrenia patient)
were excluded from the analysis because they did not
complete the DSSI. Hence, the results were based on
185 non-patients (45.4% male) and 40 patients (30%
male) with depression and 70 (50.0% male) with schizo-
phrenia. The clinical sample who was recruited from
Boramae Medical Center outpatient clinic met the
DSM-IV diagnostic criteria for either schizophrenia or
depression as determined by two psychiatrists (YK and
HYJ). The non-patient group consisted of the families
and friends of hospital staffs and community volunteers.
They were all screened by a psychiatrist with the Struc-
tured Clinical Interview for DSM-IV Axis I Disorder
(SCID-I) for presence of any mental illnesses, but none
of them were excluded from the study by this procedure.
Informed consent form was received from all subjects
prior to any study procedures and this study has been
approved by the Ethics Committee of Boramae hospital
(06-2008-29).Measures
Both non-patients and clinical sample completed the
DSSI and the Minnesota Multi-phasic Personality Inven-
tory (MMPI-2). The Hamilton Depression Rating Scale
(HAMD-17) [17] was completed only by the clinical
sample, and the 8-item remission subscale of the Positive
and Negative Syndrome Scale (PANSS) [18] was com-
pleted by psychiatrist (HYJ) only for the patients with
schizophrenia. Brief descriptions of the scales, the
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symptom-free state in this study are as follows:
DSSI
The DSSI consists of 84 items all prefixed by ‘recently’,
emphasizing the respondent’s current state. The inven-
tory contains 12 sets of seven items, each set corre-
sponding to a “personal illness syndrome”, a term
favored by Foulds in place of mental illness. The items
are scored from zero to three, according to endorsement
of the item, degree of distress experienced, the frequency
of occurrence or the certainty of belief. A person is cate-
gorized as having symptoms if he or she scores four or
more on any one or more of the 12 sets [19]. Though it
had been suggested that a person scoring four or more
on any one or more of the 12 sets can be categorized as
having symptoms, at least two symptoms from a particu-
lar category was required in order to receive a syndrome
group diagnosis to allow for some degree of misreading
or misunderstanding by the respondent [13]. Each indi-
vidual then was diagnosed as belonging to a class of dis-
order (NPI, DS, NS, ID, or DD) in accordance with the
class of the highest level syndromal group to which the
patient belonged. When an individual did not conform
to the model, e.g. scoring on ID and NS without scoring
on DS, the highest scored class was assigned and such
nonconformity to the model was noted. The scale was
translated into Korean by JSC, examined by a profes-
sional Korean linguist for appropriateness of expression,
and then back-translated into English by a graduate-level
bilingual (SSH).
MMPI-2
The Korean version of the MMPI-2 [20] consists of vari-
ous validity scales and 10 clinical scales. This study did
not exclude subjects based on any MMPI-2 validity
scales to avoid exclusion of those in the most severe
state of illness for a more accurate cross-validation with
the DSSI. Among the 10 clinical scales, only 1 (Hs:
Hypochondriasis), 2 (D: Depression), 3 (Hy: Hysteria), 4
(Pd: Psychopathic Deviation), 6 (Pa: Paranoia), 7 (Pt:
Psychasthenia), 8 (Sc: Schizophrenia), 9 (Ma: Hypo-
mania) were included in the analysis, leaving out 5 (Mas-
culine/femininity) and 0 (Social Introversion), and the
cut-off score of t > =65 was applied as indicating pres-
ence of significant psychiatric symptom [21]. Hence, if a
person does not score above 65 on any of the clinical
scales, it was assumed to be indicative of symptom-free
status.
HAMD-17: HAMD-17 is an interviewer-administered
and rated measure whose scores can range from 0 to 54.
It includes items such as overall depression, guilt, sui-
cide, insomnia, problems related to work, psychomotor
retardation, agitation, anxiety, and loss of weight andloss of insight. With higher score signifying more severe
levels of depression, scores between 0 and 6 indicate a
normal person or a symptom-free patient in remission.
The Korean version of the HAMD-17 used was found to
show high interrater reliability (r = .94, p < .001) with in-
ternal consistency of .76 (Cronbach’s α) in a validation
study with 33 inpatients and 70 outpatients diagnosed as
major depressive disorder or depressive episode of bipo-
lar I disorder according to the DSM-IV criteria [22].
PANSS
Eight PANSS items based on 3 primary symptom do-
mains of psychoticism, disorganization, and negative
symptoms (psychomotor poverty) have been rated [23].
These items have been selected by Andreasen et al. [18]
to define remission in schizophrenia. Patients must score
less than or equal to 3 (mild) on these eight items and
this must be maintained for at least 6 months to earn
remission status. In this study, however, due to cross-
sectional nature of our design, we did not apply the dur-
ation requirement. The scale items in this study were
derived from the validation study of the Korean version
of the PANSS which showed high interrater reliability
(positive syndromes subscale = .92, negative syndromes
subscale = .86) and test-retest reliability ranging from .89
to .95 [24].
Analysis
The results were largely analyzed in two steps. First, the
feasibility of the DSSI as a reliable self-report instrument
for assessment of psychiatric symptoms was examined.
This was done by examining the fitness of the hierarch-
ical model of personal illness proposed by Foulds, where
the inter-class relationship is a “hierarchical non-
reflexive logically inclusive one” [13]. It simply means
that any person identified to be in one particular class
will also meet the qualifications for all the lower classes
but not any of the higher classes. We also examined the
distribution of the DSSI classes in each subgroup, i.e.
schizophrenia and depression patients and non-patients.
Second, we calculated the power (1- β) of the DSSI,
where β signifies the false negative rate (Type I error) or
failure to detect the presence of symptoms indicated by
other criterion measures. Such would be a case where,
for example, a person with schizophrenia who was clas-
sified as being NPI on the DSSI presented non-remitted
status on the PANSS and HAMD-17 and clinically sig-
nificant level of score of > = 65 on any of the MMPI-2
clinical scales. In addition to also deriving α (Type II
error), or false positive rate, the same values were
obtained for the MMPI-2 against other measures for a
direct comparison with the DSSI. We further examined
the validity of Fould’s hypothesis of hierarchical struc-
ture model of illness by stratifying the groups according
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mean MMPI-2 clinical scale scores. All statistical proce-
dures were carried out using the SPSS 15.0 (SPSS Inc.,
Chicago, IL) with statistical significance set at p < .05.Results
The fitness of the DSSI hierarchical model
The fitness of the hierarchical model of personal illness
proposed by Foulds was examined in light of various
demographic and clinical variables and the results are
presented in Table 1. The rate of conformity of the data
to the proposed hierarchical model reached 91.2% for all
subjects. Among the conforming participants, highest
conformity was found among those in the age of 30’s
and in control group. Within the clinical samples, those
with less than 1 year of illness showed the highest con-
formity, followed by those with more than 10 years of
illness.
Presented on Table 2 is the frequency of non-
conforming DSSI patterns in each diagnostic group.
Among 26 (8.8%) non-conforming participants, 5 (1.7%)
scored on NS as their highest class, 14 (4.1%) on ID, and
7 (2.4%) on DD. Only the schizophrenia group showed
non-conforming patterns at DD, whereas both non-
patient and depression groups showed non-conforming
patterns at ID.The distribution of the DSSI classes according to
diagnostic groups
Presented in Figure 1 is the distribution of the DSSI
classes according to diagnostic groups and it includes
graphs of all and of only the conforming subjects. Evi-
dent in both graphs are the steady decreasing rate of the
control and increasing rate of the schizophrenia group
with higher classes with symptoms. As for the depres-
sion patients, they showed a steady falling trend with
higher classes only when the conforming subjects were
included.Table 1 Fitness of the hypothesized hierarchical class
structure of the DSSI according to gender, age,
diagnostic group, and duration of illness (n: % within)
Gender Male (131: 89.2), Female (164: 92.6)
Age Below 20 (16: 81.3), 20–29 (89: 87.6), 30-39 (103: 97.1),
40-49 (45: 88.9), above 50 (40: 90.0)
Diagnostic
Group




Below 1 yr. (27: 92.6), 1–3 yrs. (16: 81.3), 3–5 yrs.
(9: 66.7), 5–10 yrs. (17: 70.6), Over 10 yrs. (35: 85.7)
Total 295: 91.2
aBased on 104 data due to 6 unknown cases.Power of the DSSI to detect presence of psychiatric
symptoms
Presented on Table 3 is the power (1- β) of the DSSI to
detect presence of psychiatric symptoms on other criter-
ion measure for each subgroup based on 265 subjects
who completed the MMPI-2 (63 schizophrenia, 36 de-
pression, 166 non-patient). We have also included α
(Type II error), or false positive rate. These values are
also presented for MMPI-2 against other measures for
comparison. Here, regardless of the conformity to the
DSSI model, any subjects who scored on any DSSI
subscale, i.e. subjects who were not classified as NPI,
was regarded as indicating some psychiatric symptom.
The results showed that the DSSI has relatively high
levels of power (1- β) for all measures across all groups.
The power of the DSSI to detect presence of any psychi-
atric symptoms in the total sample, non-patient, and
clinical subgroups based on MMPI-2 as the criterion
measure all reached over .80. Furthermore, the DSSI
showed higher levels of power than MMPI-2 in
detecting presence of any psychiatric symptoms in de-
pression patients, applying the HAMD-17 remission sta-
tus criterion. In patients with schizophrenia, the DSSI
showed similar levels of power as MMPI-2 in detecting
presence of psychiatric symptoms using both HAMD-17
and PANSS remission criteria.
In terms of the Type II error, the DSSI showed the
highest level of false positive rate in patients with schizo-
phrenia on HAMD-17 remission criteria, but otherwise
false positive rate was kept under .20 for other sub-
groups and the total group in all measures.
MMPI-2 clinical scale profiles according to 5 DSSI classes
Presented in Figure 2 are the MMPI-2 clinical scale pro-
files of the 5 DSSI classes for all subjects (including
those who do not conform to the model) and each
subgroup.
For all subjects, none of the mean clinical scale scores
of MMPI-2 were above 55 for the NPI class. As for the
DS class, only the D(2) clinical scale peaked above 55.
For the NS class, only D(2) and Pt(7) peaked above the
score of 60. For the ID class, D(2), Pd(4), Pa(6), Pt(7),
and Sc(8) showed relatively high score peaking above 60,
and for the DD class, the mean scores of all clinical
scales were highest among the classes but D(2), Pa(6),
Pt(7), and Sc(8) in particular reached the clinically sig-
nificant score of 65.
In case of non-patient group, the NPI class scored
slightly lower than the DS class across all clinical scales,
and the NS class showed some overlap in scores with
the NPI class. The highest scores among the classes
were obtained from the ID class in Pd(4), Pa(6), Pt(7)
and SC(8) scales, and no one was categorized as DD
from this group.
Table 2 Frequency of non-conforming DSSI patterns according to the diagnostic group
Assigned class Pattern Non-patient (n = 185) Depression (n = 40) Schizophrenia (n = 70) Total (n = 295)
NS (0 1 0 0) 2 0 3 5
ID (1 0 1 0) 3 4 1 8
(0 1 1 0) 1 1 0 2
(0 0 1 0) 2 2 0 4
DD (1 0 0 1) 0 0 1 1
(1 1 0 1) 0 0 4 4
(1 0 1 1) 0 0 1 1
(0 1 0 1) 0 0 1 1
Total 8 7 11 26
DSSI Delusions-Symptoms-States Inventory, NS Neurotic symptoms, ID Integrated delusions, DD delusions of disintegration.
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any mean clinical scale score over 55. The DS class
showed scores of over 55 on D(2), Hy(3), Pd(4), and
Pt(7) clinical scales, but D(2) had the most pronounced
peak, being the only scale to reach the clinically signifi-
cant score of 65. The NS class showed two peaks
reaching over the score of 65, i.e. D(2) and Pt(7). As for
the ID class, only D(2) peaked over 65, but Pa(6), Pt(7),
and Sc(8) were scored closely to 65. There were only 2
in the DD class and collapsing those with those in the
ID class would have resulted in raising the mean scores
of Pa(6), Pt(7), and Sc(8) to the clinically significant level
in addition to D(2) for the combined group.
Lastly, for the schizophrenia subgroup, a large overlap
in scores was observed between the NPI and ID classes,Figure 1 Distribution of the DSSI classes according to diagnostic grou
Inventory; NPI, not personally ill; DS, dysthymic states; NS, neurotic symptomwith none of the clinical scales reaching scores higher
than 55. For the NS class, similar to the depression pa-
tients, most scales were above the score of 55, but only
D(2) and Pt(7) reached the clinically significant score of
65. The ID class showed Pt(7) and Sc(8) to be the
highest scoring subscales right below 65, and the DD
class had Pa(6), Pt(7), and Sc(8) scoring well over 65.
The MMPI-2 clinical scale profiles of the 5 DSSI clas-
ses that included only those who conformed to the DSSI
model did not noticeably differ from the overall trend
presented here, except that 1) the ID class in the depres-
sion group showed clinically significant mean scores of
over 65 on Pd(4), Pt(7), and Sc(8) scales and 2) the NS
class in the schizophrenia group also showed mean
scores of over 65 on D(2), Pd(4), Pt(7).ps (% within each group). DSSI, Delusions-Symptoms-States
s; ID, integrated delusions; DD, delusions of disintegration.
Table 3 Type I and II error and power of the DSSI against other criterion measures in each subgroup
Group Measure Criterion Type I error Power Type II error
β (1- β) (α)
Control DSSI MMPI-2 .16 .84 .11
Depression DSSI HAMD-17 Remission .08 .92 .13
MMPI-2 .08 .92 .17
MMPI-2 HAMD-17 Remission .17 .83 .08
Schizophrenia DSSI PANSS Remission .17 .83 .19
HAMD-17 Remission .00 1.00 .39
MMPI-2 .14 .86 .06
MMPI-2 PANSS Remission .16 .84 .27
HAMD-17 Remission .02 .98 .48
Depression + Schizophrenia DSSI HAMD-17 Remission .03 .97 .29
MMPI-2 .12 .88 .10
MMPI-2 HAMD-17 Remission .05 .95 .34
Total DSSI MMPI-2 .14 .86 .11
DSSI Delusions-Symptoms-States Inventory, MMPI-2 Minnesota multiphasic personality inventory, HAMD-17 Hamilton depression rating scale (17-item),
PANSS Positive and negative syndromes scale.
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In this study, the high rate of model conformity across
the samples and cross-validation with other criterion
measures provided empirical support for the DSSI hier-
archical class organization and demonstrated its poten-
tial usefulness as a self-report measure for assessment of
presence and severity of symptoms.
Our finding on the DSSI model conformity based on
all subjects (91.1%) was consistent with the majority of
the past studies [13]. The model conformity of the
schizophrenia group (84.3%) was also comparable to
those of previous studies including chronic inpatients
which ranged from 73.8% to 85.0% [14,25,26]. On the
other hand, the conformity rate of our depression group
(82.5%) was lower than that of one other study reported
on depression group involving only inpatients (92.3%)
[27]. Among the nonconforming patients, 71% had dur-
ation of illness of longer than 5 years and this seemed to
well correspond to the overall decline in the rate of
model conformity with chronicity of illness. The
nonconforming depression patients were all categorized
within DI and there may be a distinct possibility that
some of them may have major depression with psychotic
features. Such patients have been found to have longer
duration of episodes and greater recurrence than those
with nonpsychotic depression [28]. Nonetheless, further
examination of the relationship between the duration of
illness and model conformity is warranted for the de-
pression patients due to a relatively small sample size in
our study.
A closer examination of the non-conforming patterns
yielded an interesting observation that of 26 non-conforming participants, the overwhelming majority (23
participants including 5 of the NS class) did not report
the symptoms of the adjacent subordinate class.
Angelopoulos and Economous also reported a compar-
ably high proportion (32 out of 47 non-conforming par-
ticipants including 7 of the NS class) that did not report
the symptoms of the adjacent subordinate class among
the inpatients with schizophrenia [11]. Such results sug-
gested that it may be more common for symptoms of
one class to overshadow those of the adjacent subor-
dinate class than of any other subordinated classes,
which may be an important addition to Foulds’ sugges-
tion that symptomatology from the higher class may
mask, confuse, override, or distract from that in the
lower classes [29].
The majority of past studies on the distribution of the
DSSI classes have been conducted on general psychiatric
patients and those involving specific psychiatric groups
all dealt exclusively with inpatients except for one study
that included day-patients [30]. This was in keeping with
the notion that the hierarchical model is applicable only
to acute patients [13,26]. Hence, no other study has in-
cluded a large number of outpatients with chronic
schizophrenia, not to mention non-patients – apart from
that by the original authors of the DSSI [10]. The results
of our study however suggested that the DSSI can be ap-
plied as effectively to both subclinical stabilized chronic
illness group and non-patients as a screening measure
for presence of active symptoms. The sensitivity and
specificity of the DSSI in detecting the presence of
symptoms among schizophrenia and depression patients
was comparable to those of MMPI-2 clinical scales in
All Subjects                                                                                                  Non-patient
Depression                                                                                                   Schizophrenia
Figure 2 MMPI-2 clinical scale profiles of 5 DSSI classes in all subjects and according to diagnostic group. DSSI, Delusions-Symptoms-
States Inventory; MMPI-2, Minnesota Multiphasic Personality Inventory; NPI, not personally ill; DS, dysthymic states; NS, neurotic symptoms;
ID, integrated delusions; DD, delusions of disintegration. Hs, hypochondriasis; D, depression; Hy, hysteria; Pd, psychopathic deviation; Pa, paranoia;
Pt, psychasthenia; Sc, Schizophrenia; Ma, Hypomania.
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PANSS, all of which require more time and trained staff.
Lastly, there are a number of important issues that should
be raised prior to generalizing the results of our study. First,
our results need to be considered in light of the Berkson’s
fallacy: since our non-patient group has been screened with
SCID-I, whilst none had been excluded by this process,
there is a possibility that the composition of our non-
patient group may actually under-represent the individuals
with more severe levels of illness [31]. Also, the clinical
group was not screened for comorbidity of psychiatric ill-
ness, not to mention alcohol dependence, with DSM-IV by
the psychiatrists. Furthermore, inclusion of other diagnostic
groups, such as anxiety or personality disorders, was not
considered in our study design. Since such factors may have
significant affect on the conformity of the model, future
studies using broader range of diagnose and more refinedstudy design are warranted to lend further support for the
validation of the DSSI.
Conclusions
In summary, the results of the present study provided
further support for the utility of the DSSI in covering a
relatively wide range of psychiatric symptom spectrum.
It may be usefully applied for not only the detection of
presence of psychiatric symptoms among non-patient
groups but also assessment of alleviation or aggravation
of illness in patients. The DSSI can thereby provide
complementary information for diagnosis, determination
of the treatment efficacy, and decisions concerning
maintenance of treatment strategy.
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